急性淋巴细胞白血病患儿外周血T细胞表面CD28、CTLA-4的表达及其临床意义
摘要
目的探讨急性淋巴细胞白血病患儿外周血T细胞上共刺激分子CD28、CTLA-4表达及其临床意义。
方法利用流式细胞仪(FCM)技术检测21例初发急性淋巴细胞白血病患儿(其中5例为高白细胞患儿)和20例正常儿童外周血淋巴细胞CD4+和CD8+T细胞表面CD28和CTLA-4的表达,比较CD4/CD8的比例变化,分析其与白血病发病的关系。
结果与正常对照组比较，ALL患儿外周血CD4+T淋巴细胞上CD28的表达明显下降(t=4.796，p<0.05)；CD8+T淋巴细胞上CD28的表达明显下降(t=3.551,p<0.05)。CD4+T淋巴细胞上CTLA-4的表达明显升高(t=5.07，p<0.05)；CD8+T淋巴细胞上CTLA-4的表达明显升高(t=5.469，p<0.05)。高白细胞组与低白细胞组比较,CD4+和CD8+T淋巴细胞上CD28的表达差异均没有统计学意义(t=0.16,t=0.712,p>0.05)：CTLA-4的表达也没有明显的统计学意义(t=0.363，t=0.65,p>0.05)。ALL患儿外周血CD4/CD8明显下降(t=3.477,p<0.05),差异有统计学意义。
结论ALL患儿外周血T淋巴细胞上CD28表达下降,CTLA-4的表达升高；CD4+的T细胞数量下降,CD4/CD8比值下降,提示T淋巴细胞的免疫活化能力降低,免疫监视功能下降,可能是ALL的发病机制之一。
Objective To investigate the expression of costimulatory molecules CD28 and CTLA-4 on peripheral blood T lymphocytes in patients with Acute Lymphoblastic Leukemia(ALL) and to explore their possible clinical significance.
Methods The expression of costimulatory molecules CD28 and CTLA-4 on CD4+and CD8+T cells were measured in 21 patients(5 patients with high white blood cell) with newly diagnosed ALL and 20 healthy subjects as control group by flow cytometry(FCM).The expression of the peripheral blood T lymphocyte subsets CD4/CD8 was compared and its relationships with ALL was analyzed.
Results The level of CD28 on CD4+T cells and on CD8+T cells of ALL were significantly decreased compared with normal controls(t=4.796,t=3.551 respectively, p<0.05);The levels of CTLA-4 on CD4+T cells and on CD8+T cells of ALL were significantly increased compared with normal controls(t=5.07,t=5.469 respectively, p<0.05). The level of CD28 on CD4+and CD8+T cell had no statistical significance between high and low white blood cell group(t=0.160, t=0.712 respectively, p>0.05). And the level of CTLA-4 also had no statistical significance(t=0.363, t=0.650 respectively,p>0.05). The level of CD4/CD8 was significantly decreased in ALL patients than in normal controls (t=3.477, p<0.05).
Conclusion The expression of CD28 on peripheral blood T cell in ALL patients was decreased, however, the expression of CTLA-4 was up-regulated. The CD4+T cell and the ratio of CD4/CD8 were also decreased, which were suggested that the ability of immune activation in T cell was decreased, and the immune surveillance also descended, these may be one of the pathogenesis of ALL.
方法利用流式细胞仪(FCM)技术检测21例初发急性淋巴细胞白血病患儿(其中5例为高白细胞患儿)和20例正常儿童外周血淋巴细胞CD4+和CD8+T细胞表面CD28和CTLA-4的表达,比较CD4/CD8的比例变化,分析其与白血病发病的关系。
结果与正常对照组比较，ALL患儿外周血CD4+T淋巴细胞上CD28的表达明显下降(t=4.796，p<0.05)；CD8+T淋巴细胞上CD28的表达明显下降(t=3.551,p<0.05)。CD4+T淋巴细胞上CTLA-4的表达明显升高(t=5.07，p<0.05)；CD8+T淋巴细胞上CTLA-4的表达明显升高(t=5.469，p<0.05)。高白细胞组与低白细胞组比较,CD4+和CD8+T淋巴细胞上CD28的表达差异均没有统计学意义(t=0.16,t=0.712,p>0.05)：CTLA-4的表达也没有明显的统计学意义(t=0.363，t=0.65,p>0.05)。ALL患儿外周血CD4/CD8明显下降(t=3.477,p<0.05),差异有统计学意义。
结论ALL患儿外周血T淋巴细胞上CD28表达下降,CTLA-4的表达升高；CD4+的T细胞数量下降,CD4/CD8比值下降,提示T淋巴细胞的免疫活化能力降低,免疫监视功能下降,可能是ALL的发病机制之一。
Objective To investigate the expression of costimulatory molecules CD28 and CTLA-4 on peripheral blood T lymphocytes in patients with Acute Lymphoblastic Leukemia(ALL) and to explore their possible clinical significance.
Methods The expression of costimulatory molecules CD28 and CTLA-4 on CD4+and CD8+T cells were measured in 21 patients(5 patients with high white blood cell) with newly diagnosed ALL and 20 healthy subjects as control group by flow cytometry(FCM).The expression of the peripheral blood T lymphocyte subsets CD4/CD8 was compared and its relationships with ALL was analyzed.
Results The level of CD28 on CD4+T cells and on CD8+T cells of ALL were significantly decreased compared with normal controls(t=4.796,t=3.551 respectively, p<0.05);The levels of CTLA-4 on CD4+T cells and on CD8+T cells of ALL were significantly increased compared with normal controls(t=5.07,t=5.469 respectively, p<0.05). The level of CD28 on CD4+and CD8+T cell had no statistical significance between high and low white blood cell group(t=0.160, t=0.712 respectively, p>0.05). And the level of CTLA-4 also had no statistical significance(t=0.363, t=0.650 respectively,p>0.05). The level of CD4/CD8 was significantly decreased in ALL patients than in normal controls (t=3.477, p<0.05).
Conclusion The expression of CD28 on peripheral blood T cell in ALL patients was decreased, however, the expression of CTLA-4 was up-regulated. The CD4+T cell and the ratio of CD4/CD8 were also decreased, which were suggested that the ability of immune activation in T cell was decreased, and the immune surveillance also descended, these may be one of the pathogenesis of ALL.
引文
[1]诸福堂,胡亚美,江载芳.诸福堂实用儿科学[M].修订7版.北京：人民卫生出版社,2002：2200-2208.
[2]Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosureillance and immunoediting[J]. Immunity,2004,21 (2):137-148.
[3]Sengupta N, Macfie TS, Macdonald TT, etal. Cancer immunoediting and "spontaneous" tumor regression[J].Pathol Res Pract.2010,206(1):1-8.
[4]Barbara Seliger,Francesco M, Marincola. The complex role of B7 molecules in tumor immunology[J]. Trends Mol Med.2008,14(12):550-559.
[5]Carreiio LJ, Pacheco R, Gutierrez MA, etal. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells[J].Immunology. 2009,128(3):334-341.
[6]Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation[J]. Immunol Rev.2009,229(1):307-321.
[7]Simone, Joseph V. History of the treatment of childhood ALL:a paradigm for cancer cure[J].Best Pract Res Clin Haematol.2006,19(2):353-359.
[8]Dustin ML,Cooper JA. The immunological synaspse and the action cytoskeleton: molecular hardware for T cell signaling[J]. Nat Immunol.2000,1(1):23-29.
[9]Bocko D, Kosmaczewska A, Ciszak L, etal.CD28 costimulatory molecule-expression, structure and function[J]. Arch Immunol Ther Exp.2002,50(3):169-177.
[10]Chang TT, Kuchroo VK, Share AH. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease[J].Cure Dir Autoimmune.2002,5(1):113.
[11]Kosmaczewska A, Frydecka I, Bocko D, etal. Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production[J]. Br J Haematol. 2002,118(1):202-209.
[12]Frydecka I, Kosmaczewska A, Bocko D, etal. Alteration of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4)molecules in patients with B-cell chronic lymphocytic leukaemia[J]. Br J Cancer. 2004,90(10):2042-2048.
[13]翟士军,苏成海.B7-CD28家族分子的免疫调节功能及临床应用[J].放射免疫学杂志.2008,21(6)：575-578.
[13]Londsten T,Lee KP, Harris ES, etal. Characterization of CTLA-4 structure and expression on human T cell[J].J Immunol.1993,151(7):3489-3499.
[14]Blair PJ, Riley JL, Levine BL, etal. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction[J].J Immunol.1998,160(1):12-15.
[15]Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta production by murine CD4+T cell[J].J Exp Med.1998,188(10):1849-1857.
[16]MA Xiao-Rong, ZHANG Wang-Gang, etal. Expression og CD28 and CD137 in peripheral blood T cells in acute leukemia[J]. J Fourth Mil Med Univ. 2003,24(19):1787-1789.
[17]钱素英,张顺,陈亚敏,等.恶性淋巴瘤患者外周血T细胞CD8+CD28-表达及意义[J].浙江实用医学.2008,13(6)：399-422.
[18]Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia:evidence of immune dysregulation[J].Br J Haematol.2001,112(4):959-964.
[19]薛月华,蔡逸婷,谢匡成.CD28/CD152：CD80/CD86分子在强直性脊柱炎患者外周血淋巴细胞上的表达[J].检验医学.2008,23(5)：478-480.
[20]Perez-Garcia A, Brunet S, Berlanga JJ, etal. Ctla-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy[J].Leukemia.2009,23(3):486-491.
[21]Pardali K, Moustakas A. Actions of TGF-P as tumor suppressor and Pro-metastatic factor in human cancer[J]. Biochim Biophys Acta.2007,1775(1):21-62.
[22]Perez N,Karumuthil-Melethil S, Li RB, etal. Preferential costimulation by CD80 results in IL-10-dependent TGF-β1+-adaptive regulatory T cell generation[J]. J Immunol.2008,180(10):6566-6576.
[23]张翔,何广胜,吴德沛,等.骨髓增生异常综合征患者骨髓CD4+T细胞共刺激分子CD28/CTLA-4的变化[J].苏州大学学报.2008,28(5)：782-784.
[24]Borriello F, Sethna MP, Boyd SD, etal.B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation[J]. Immunity.1997,6(3):303-313.
[25]Dong C, Juedes AE, Temann UA, etal. ICOS costimulatory receptor is essential for T-cell activation and function[J]. Nature.2001,409(6816):97-101.
[26]Nurieva RI.Mai XM, Forbush K,Bevan MJ, Dong C. B7h is required for T cell activation, differentiation, and effector function[J]. Proc Natl Acad Sci USA.2003,100(24):14163-14168.
[27]Nurieva RI, Duong J, Kishikawa H, etal. Transcriptional regulation of th2 differentiation by inducible costimulator[J]. Immunity.2003,18(6):801-811.
[28]Dong C, Nurieva RI. Regulation of immune and autoimmune responses by ICOS[J].J Autoimmun.2003,21(3):255-260.
[29]Nurieva RI, Thomas S, Nguyen T, etal. T-cell tolerance or function is determined by combinatorial costimulatory signals[J]. Embo J.2006,25(11):2623-2633.
[30]Park H, Li Z, Yang XO, etal. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J]. Nat Immunol. 2005,6(11):1133-1141.
[1]Barbara Seliger,Francesco M,Marincola.The complex role of B7 molecules in tumor immunology[J].Trends Mol Med.2008,14(12):550-559.
[2]Selvakumar A,White PC,Dupont B.Genomic organization of the mouse B-lymphocyte activation antigen B7 [J].Immunogenetics.1993,38 (4):292.
[3]Rau FC,Dieter J.B7-1/2 direct signaling to B cells enhances IgG secretion[J].J Immunol.2009,183(12):7661-7671.
[4]Xu L,Li ZL.Expression of B7-related protein-1 on human coronary artery endothelial cells and its clinical significance[J].Nan Fang Yi Ke Da Xue Xue Bao.2009,29(8):1623-1625.
[5]Aicher A,Hayden LM,Brady WA,etal.Characterization of human inducible costimulator ligand expression and function [J].J Immunol.2000,164(9):4689-4696.
[6]Yoshinaga SK,Zhang M,Pistillo J,etal.Characterization of a new human B7-related protein:B7RP-1 is the ligand to the costimulatory protein ICOS[J].Int Immunol.2000,12(10):1439-1447.
[7]Yoshinaga SK.Whofiskey JS.Khare SD,etal.T-cell co-stimulation through B7RP-1 and ICOS [J].Nature.1999,402(6763):827-832.
[8]Dong H,Zhu QTamada K,etal.B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion [J].Nat Med.1999, 5(12):1365-1369.
[9]Seo SK, Seo HM, Jeong HY, etal.Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response[J].Immunol Lett.2006,102(2):222-228.
[10]Tseng SY, Otsuji M, Gorsaki K, etal.B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cell [J].J Exp Med.2001,193(7):839-845.
[11]Selenko-Gebauer N,Majdic O,Szekeres A,etal.B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy [J]. J Immunol.2003,170(7):3637-3644.
[12]Tamura H,Dong H,Zhu G,etal.B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function [J].Blood.2001,97(6):1809-1816.
[13]Dong C,Temann UA,Flavell RA.Cutting edge:critical role of inducible costimulator in germinal center reactions[J].J Immunol.2001,166(6): 3659-3662.
[14]Sun X,Vale M,Leung E,etal.Mouse B7-H3 induces antitumor immunity[J].Gene Ther.2003,10(20):1728-1734.
[15]Chapoval AI,Ni J,Lau JS,etal.B7-H3:a costimulatory, molecule for T cell activation and IFN-Y production[J].Nat Immunol.2001,2(3):269-274.
[16]Sica CL,Choi IH,Zhu Qetal.B7-H4, a molecule of the B7 family, negatively regulates T cell immunity[J].Immunity.2003,18(6):849-861.
[17]Prasad D V,Richards S,Mai XM,etal.B7SI,a novel B7 family member that negatively regulates T cell activation[J].Immunity.2003,18(6):863-873.
[18]Zang X,Loke P,Kim J,etal.B7X:a widely expressed B7 family member that inhibits T cell activation[J].Proc Natl Acad Sci USA.2003,100(18):10388-10392.
[19]Hirotsune S.Yoshida N,Chen A,etal.An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene[J].Nature.2003,423(6935):91-96.
[20]Yang Y,Liu XK,Nguyen T,etal.Characterization of B7S3 as a novel negative regulator of T cell[J].J Immunol.2007,178(6):3661-3667.
[21]Natalia Martin-Orozco,Chen Dong.Inhibitory costimulation and anti-tumor immunity[J].Semin Cancer Biol.2007,17(4):288-298.
[22]Chang TT,Kuchroo VK,Share AH.Role of the B7-CD28/CTLA-4 pathway in autoimmune disease[J].Cure Dir Autoimmune.2002,5(1):113.
[23]Hutloff A,Diurich AM,Berer KC,etal.ICOS is an inducible T-cell co stimulator structurally and functionally related to CD28[J].Nature.1999,397(6716):263-266.
[24]Coyle A J,Lehar S,Lloyd C,etal.The CD28 related molecule ICOS is required for effective T cell-depended immune responses[J].Immunity.2000,13(1):95-105.
[25]Chambers CA.The expanding world of co-stimulation:the two-signal model revisited[J].Trends Immuol.2001,22(4):217-224.
[26]Raveteh J V,Lanier L L.Immune inhibitory receptors[J].Scienee.2000,290:84-89.
[27]Watanabe N, Gavrieli M, Sedy JR,etal. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 [J].Nat Inmunol.2003,4(7):670-679.
[28]Gavrieli M,Watanabe N,Loftin SK,etal.Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2[J]. Biochem Biophy Res Commun.2003,312(4):1236-1243.
[29]Gavrieli M,Sedy J,Nelson CA,Murphy KM.BTLA and HVEM cross talk regulates inhibition and costimulation[J]. Adv Immunol.2006,92:157-185.
[30]Montgomery RI,Warner MS,Lum BJ,Spear PGHerpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family[J]. Cell.1996,87(3):427-436.
[31]Gonzalez LC,Loyet KM,Calemine-Fenaux J,etal.A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator[J].Proc Natl Acad Sci USA. 2005,102(4):1116-1121.
[32]Kwon BS,Tan KB,Ni J.etal.A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation[J].J Biol Chem.1997,272(22):14272-14276.
[33]Favero J,Lafont V.Effector pathways regulating T cell activation[J].Biochem Pharmacol.l998,56(12):1539-1547.
[34]Jang IK,Zhang J.Grb2,a simple adapter with complex roles in lymphocyte development, function, and signaling[J].Immunol Rev.2009,232(1):150-159.
[35]Charruyer A,Jean C.PKCzeta protects against UV-C-induced apoptosis by inhibiting acid sphingomyelinase-dependent ceramide production[J].Biochem J.2007,405(1):77-83.
[36]Suwalska K, Pawlak E, Karabon L, etal. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population[J].Hum Immunol.2008,69(3):193-201.
[37]Kosaka K,Yashiro M,Sakate Y,Hirakawa K.A synergistic antitumor or effect of interleukin-2 addition with CD80 immunogene therapy for peritoneal metastasis of gastric carcinoma[J].Dig Dis Sci.2007,52(8):1946-1953.
[38]范萍,王水,刘晓,等.乳腺癌患者B7-CD28共刺激通路的研究.[J]中华普通外科杂志.2003,18(3)：162-164.
[39]Kruger K,Buning C,Schriever F.Activated T Lymphocytes bind in situ to stromal tissue of colon carcinoma but lack adhesion to tumor cells[J].Eur Immunol.2001,31(1):138-145.
[40]Puliti M,Bistoni F,Tissi L.Lack of B7-1 and B7-2 costimulatory molecules modulates the severity of group B Streptococcus-induced arthritis[J].Microbes Infect.2010,12(4):302-308.
[41]宋晓翔,丰其华,李晓忠,等.过敏性紫癜患儿外周血单个核细胞共刺激分子B7-1、B7-2与CD28的表达及意义[J].苏州大学学报.2006,26(5)：805-808.
[42]程昉,韩星海,杨佳荟,等.系统性红斑狼疮患者外周血淋巴细胞CD80和CD86的表达[J].中国内科杂志.2004,43(8)：614-615.
[43]吴怀国,彭晓江,李军,等.共刺激分子CD28:CTLA4/B7在实验性自身免疫性重症肌无力中的作用[J].临床神经病学杂志.2008,21(3)：210-212.
[44]祝戎飞,黄爱霞.协同刺激分子CD28/B7及CD40/CD40L在哮喘特异性免疫治疗中的作用[J].华中医学杂志.2006,30(4)：278-280.
[45]张仪,韩波.CD28在疾病治疗中的作用研究进展[J].实用儿科临床杂志.2008,23(15)：1204-1206.
[46]Fan k,Wang H,Wei H.etal.Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance[J].Transplantation.2007,84(6):746-754.
[47]李辉,石理华,叶启发,等.肾移植受者外周血中共刺激分子CD28与CD40/CD152的表达研究[J].中国现代医学杂志.2008,18(1)：85-89.
[48]高锐,薛学义,毛厚平.ICOS/B7RP-1共刺激通路在大鼠慢性移植物失功中作用的研究[J].齐齐哈尔医学院学报.2009,30(14)：1668-1670.
[49]Li N,Zhu F,Gao F.Blockade of CD28 by a synthetical peptoid inhibits T-cell proliferation and attenuates graft-versus-host disease[J].Cell Mol Immunol. 2010,7(2):133-142.
[50]Morita M,Fujino M,Jiang QKitazawa Y,etal.PD-1/B7 interaction contribute to the spontaneous acceptance of mouse liver allograft[J].Am J Transplant.2010,10(1):40-46.
[51]Yang J,Riella LV,Boenisch O.etal.Paradoxical functions of B7:CD28 costimulation in a MHC class-Ⅱ-mismatched cardiac transplant model[J].Am J Transplant.2009,9(12):2837-2844.
[52]Asai T,Choi BK,Kwon PM,etal.Blockade of the 4-1BB(CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice[J].Immunology.2007,121(3):349-358.
[53]Ren XF,Luo KX,Zhang L.CD80 expression in biopsy from patients with chronic hepatitis B[J]. Med J Chin PLA.2000,25 (2):115.
[54]Gilani SR,Vuga LJ,LindellKO,etal.CD28 down-regulation on circulation CD4 T-cell is associated with poor prognoses of patients with idiopathic pulmonary fibrosis[J].PloS One.2010,5(1):e8959.
[55]佡剑非,冯涓.急性脑梗死患者CD4+CD28-T淋巴细胞和肿瘤坏死因子-α变化的研究[J].中国实用内科杂志.2007,27(12)：954-955.
[56]Hu W,Janke A,Ortler S,etal.Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies[J].Neurology.2007,68(4):277-282.
[2]Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosureillance and immunoediting[J]. Immunity,2004,21 (2):137-148.
[3]Sengupta N, Macfie TS, Macdonald TT, etal. Cancer immunoediting and "spontaneous" tumor regression[J].Pathol Res Pract.2010,206(1):1-8.
[4]Barbara Seliger,Francesco M, Marincola. The complex role of B7 molecules in tumor immunology[J]. Trends Mol Med.2008,14(12):550-559.
[5]Carreiio LJ, Pacheco R, Gutierrez MA, etal. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells[J].Immunology. 2009,128(3):334-341.
[6]Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation[J]. Immunol Rev.2009,229(1):307-321.
[7]Simone, Joseph V. History of the treatment of childhood ALL:a paradigm for cancer cure[J].Best Pract Res Clin Haematol.2006,19(2):353-359.
[8]Dustin ML,Cooper JA. The immunological synaspse and the action cytoskeleton: molecular hardware for T cell signaling[J]. Nat Immunol.2000,1(1):23-29.
[9]Bocko D, Kosmaczewska A, Ciszak L, etal.CD28 costimulatory molecule-expression, structure and function[J]. Arch Immunol Ther Exp.2002,50(3):169-177.
[10]Chang TT, Kuchroo VK, Share AH. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease[J].Cure Dir Autoimmune.2002,5(1):113.
[11]Kosmaczewska A, Frydecka I, Bocko D, etal. Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production[J]. Br J Haematol. 2002,118(1):202-209.
[12]Frydecka I, Kosmaczewska A, Bocko D, etal. Alteration of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4)molecules in patients with B-cell chronic lymphocytic leukaemia[J]. Br J Cancer. 2004,90(10):2042-2048.
[13]翟士军,苏成海.B7-CD28家族分子的免疫调节功能及临床应用[J].放射免疫学杂志.2008,21(6)：575-578.
[13]Londsten T,Lee KP, Harris ES, etal. Characterization of CTLA-4 structure and expression on human T cell[J].J Immunol.1993,151(7):3489-3499.
[14]Blair PJ, Riley JL, Levine BL, etal. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction[J].J Immunol.1998,160(1):12-15.
[15]Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta production by murine CD4+T cell[J].J Exp Med.1998,188(10):1849-1857.
[16]MA Xiao-Rong, ZHANG Wang-Gang, etal. Expression og CD28 and CD137 in peripheral blood T cells in acute leukemia[J]. J Fourth Mil Med Univ. 2003,24(19):1787-1789.
[17]钱素英,张顺,陈亚敏,等.恶性淋巴瘤患者外周血T细胞CD8+CD28-表达及意义[J].浙江实用医学.2008,13(6)：399-422.
[18]Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia:evidence of immune dysregulation[J].Br J Haematol.2001,112(4):959-964.
[19]薛月华,蔡逸婷,谢匡成.CD28/CD152：CD80/CD86分子在强直性脊柱炎患者外周血淋巴细胞上的表达[J].检验医学.2008,23(5)：478-480.
[20]Perez-Garcia A, Brunet S, Berlanga JJ, etal. Ctla-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy[J].Leukemia.2009,23(3):486-491.
[21]Pardali K, Moustakas A. Actions of TGF-P as tumor suppressor and Pro-metastatic factor in human cancer[J]. Biochim Biophys Acta.2007,1775(1):21-62.
[22]Perez N,Karumuthil-Melethil S, Li RB, etal. Preferential costimulation by CD80 results in IL-10-dependent TGF-β1+-adaptive regulatory T cell generation[J]. J Immunol.2008,180(10):6566-6576.
[23]张翔,何广胜,吴德沛,等.骨髓增生异常综合征患者骨髓CD4+T细胞共刺激分子CD28/CTLA-4的变化[J].苏州大学学报.2008,28(5)：782-784.
[24]Borriello F, Sethna MP, Boyd SD, etal.B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation[J]. Immunity.1997,6(3):303-313.
[25]Dong C, Juedes AE, Temann UA, etal. ICOS costimulatory receptor is essential for T-cell activation and function[J]. Nature.2001,409(6816):97-101.
[26]Nurieva RI.Mai XM, Forbush K,Bevan MJ, Dong C. B7h is required for T cell activation, differentiation, and effector function[J]. Proc Natl Acad Sci USA.2003,100(24):14163-14168.
[27]Nurieva RI, Duong J, Kishikawa H, etal. Transcriptional regulation of th2 differentiation by inducible costimulator[J]. Immunity.2003,18(6):801-811.
[28]Dong C, Nurieva RI. Regulation of immune and autoimmune responses by ICOS[J].J Autoimmun.2003,21(3):255-260.
[29]Nurieva RI, Thomas S, Nguyen T, etal. T-cell tolerance or function is determined by combinatorial costimulatory signals[J]. Embo J.2006,25(11):2623-2633.
[30]Park H, Li Z, Yang XO, etal. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J]. Nat Immunol. 2005,6(11):1133-1141.
[1]Barbara Seliger,Francesco M,Marincola.The complex role of B7 molecules in tumor immunology[J].Trends Mol Med.2008,14(12):550-559.
[2]Selvakumar A,White PC,Dupont B.Genomic organization of the mouse B-lymphocyte activation antigen B7 [J].Immunogenetics.1993,38 (4):292.
[3]Rau FC,Dieter J.B7-1/2 direct signaling to B cells enhances IgG secretion[J].J Immunol.2009,183(12):7661-7671.
[4]Xu L,Li ZL.Expression of B7-related protein-1 on human coronary artery endothelial cells and its clinical significance[J].Nan Fang Yi Ke Da Xue Xue Bao.2009,29(8):1623-1625.
[5]Aicher A,Hayden LM,Brady WA,etal.Characterization of human inducible costimulator ligand expression and function [J].J Immunol.2000,164(9):4689-4696.
[6]Yoshinaga SK,Zhang M,Pistillo J,etal.Characterization of a new human B7-related protein:B7RP-1 is the ligand to the costimulatory protein ICOS[J].Int Immunol.2000,12(10):1439-1447.
[7]Yoshinaga SK.Whofiskey JS.Khare SD,etal.T-cell co-stimulation through B7RP-1 and ICOS [J].Nature.1999,402(6763):827-832.
[8]Dong H,Zhu QTamada K,etal.B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion [J].Nat Med.1999, 5(12):1365-1369.
[9]Seo SK, Seo HM, Jeong HY, etal.Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response[J].Immunol Lett.2006,102(2):222-228.
[10]Tseng SY, Otsuji M, Gorsaki K, etal.B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cell [J].J Exp Med.2001,193(7):839-845.
[11]Selenko-Gebauer N,Majdic O,Szekeres A,etal.B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy [J]. J Immunol.2003,170(7):3637-3644.
[12]Tamura H,Dong H,Zhu G,etal.B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function [J].Blood.2001,97(6):1809-1816.
[13]Dong C,Temann UA,Flavell RA.Cutting edge:critical role of inducible costimulator in germinal center reactions[J].J Immunol.2001,166(6): 3659-3662.
[14]Sun X,Vale M,Leung E,etal.Mouse B7-H3 induces antitumor immunity[J].Gene Ther.2003,10(20):1728-1734.
[15]Chapoval AI,Ni J,Lau JS,etal.B7-H3:a costimulatory, molecule for T cell activation and IFN-Y production[J].Nat Immunol.2001,2(3):269-274.
[16]Sica CL,Choi IH,Zhu Qetal.B7-H4, a molecule of the B7 family, negatively regulates T cell immunity[J].Immunity.2003,18(6):849-861.
[17]Prasad D V,Richards S,Mai XM,etal.B7SI,a novel B7 family member that negatively regulates T cell activation[J].Immunity.2003,18(6):863-873.
[18]Zang X,Loke P,Kim J,etal.B7X:a widely expressed B7 family member that inhibits T cell activation[J].Proc Natl Acad Sci USA.2003,100(18):10388-10392.
[19]Hirotsune S.Yoshida N,Chen A,etal.An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene[J].Nature.2003,423(6935):91-96.
[20]Yang Y,Liu XK,Nguyen T,etal.Characterization of B7S3 as a novel negative regulator of T cell[J].J Immunol.2007,178(6):3661-3667.
[21]Natalia Martin-Orozco,Chen Dong.Inhibitory costimulation and anti-tumor immunity[J].Semin Cancer Biol.2007,17(4):288-298.
[22]Chang TT,Kuchroo VK,Share AH.Role of the B7-CD28/CTLA-4 pathway in autoimmune disease[J].Cure Dir Autoimmune.2002,5(1):113.
[23]Hutloff A,Diurich AM,Berer KC,etal.ICOS is an inducible T-cell co stimulator structurally and functionally related to CD28[J].Nature.1999,397(6716):263-266.
[24]Coyle A J,Lehar S,Lloyd C,etal.The CD28 related molecule ICOS is required for effective T cell-depended immune responses[J].Immunity.2000,13(1):95-105.
[25]Chambers CA.The expanding world of co-stimulation:the two-signal model revisited[J].Trends Immuol.2001,22(4):217-224.
[26]Raveteh J V,Lanier L L.Immune inhibitory receptors[J].Scienee.2000,290:84-89.
[27]Watanabe N, Gavrieli M, Sedy JR,etal. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 [J].Nat Inmunol.2003,4(7):670-679.
[28]Gavrieli M,Watanabe N,Loftin SK,etal.Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2[J]. Biochem Biophy Res Commun.2003,312(4):1236-1243.
[29]Gavrieli M,Sedy J,Nelson CA,Murphy KM.BTLA and HVEM cross talk regulates inhibition and costimulation[J]. Adv Immunol.2006,92:157-185.
[30]Montgomery RI,Warner MS,Lum BJ,Spear PGHerpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family[J]. Cell.1996,87(3):427-436.
[31]Gonzalez LC,Loyet KM,Calemine-Fenaux J,etal.A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator[J].Proc Natl Acad Sci USA. 2005,102(4):1116-1121.
[32]Kwon BS,Tan KB,Ni J.etal.A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation[J].J Biol Chem.1997,272(22):14272-14276.
[33]Favero J,Lafont V.Effector pathways regulating T cell activation[J].Biochem Pharmacol.l998,56(12):1539-1547.
[34]Jang IK,Zhang J.Grb2,a simple adapter with complex roles in lymphocyte development, function, and signaling[J].Immunol Rev.2009,232(1):150-159.
[35]Charruyer A,Jean C.PKCzeta protects against UV-C-induced apoptosis by inhibiting acid sphingomyelinase-dependent ceramide production[J].Biochem J.2007,405(1):77-83.
[36]Suwalska K, Pawlak E, Karabon L, etal. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population[J].Hum Immunol.2008,69(3):193-201.
[37]Kosaka K,Yashiro M,Sakate Y,Hirakawa K.A synergistic antitumor or effect of interleukin-2 addition with CD80 immunogene therapy for peritoneal metastasis of gastric carcinoma[J].Dig Dis Sci.2007,52(8):1946-1953.
[38]范萍,王水,刘晓,等.乳腺癌患者B7-CD28共刺激通路的研究.[J]中华普通外科杂志.2003,18(3)：162-164.
[39]Kruger K,Buning C,Schriever F.Activated T Lymphocytes bind in situ to stromal tissue of colon carcinoma but lack adhesion to tumor cells[J].Eur Immunol.2001,31(1):138-145.
[40]Puliti M,Bistoni F,Tissi L.Lack of B7-1 and B7-2 costimulatory molecules modulates the severity of group B Streptococcus-induced arthritis[J].Microbes Infect.2010,12(4):302-308.
[41]宋晓翔,丰其华,李晓忠,等.过敏性紫癜患儿外周血单个核细胞共刺激分子B7-1、B7-2与CD28的表达及意义[J].苏州大学学报.2006,26(5)：805-808.
[42]程昉,韩星海,杨佳荟,等.系统性红斑狼疮患者外周血淋巴细胞CD80和CD86的表达[J].中国内科杂志.2004,43(8)：614-615.
[43]吴怀国,彭晓江,李军,等.共刺激分子CD28:CTLA4/B7在实验性自身免疫性重症肌无力中的作用[J].临床神经病学杂志.2008,21(3)：210-212.
[44]祝戎飞,黄爱霞.协同刺激分子CD28/B7及CD40/CD40L在哮喘特异性免疫治疗中的作用[J].华中医学杂志.2006,30(4)：278-280.
[45]张仪,韩波.CD28在疾病治疗中的作用研究进展[J].实用儿科临床杂志.2008,23(15)：1204-1206.
[46]Fan k,Wang H,Wei H.etal.Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance[J].Transplantation.2007,84(6):746-754.
[47]李辉,石理华,叶启发,等.肾移植受者外周血中共刺激分子CD28与CD40/CD152的表达研究[J].中国现代医学杂志.2008,18(1)：85-89.
[48]高锐,薛学义,毛厚平.ICOS/B7RP-1共刺激通路在大鼠慢性移植物失功中作用的研究[J].齐齐哈尔医学院学报.2009,30(14)：1668-1670.
[49]Li N,Zhu F,Gao F.Blockade of CD28 by a synthetical peptoid inhibits T-cell proliferation and attenuates graft-versus-host disease[J].Cell Mol Immunol. 2010,7(2):133-142.
[50]Morita M,Fujino M,Jiang QKitazawa Y,etal.PD-1/B7 interaction contribute to the spontaneous acceptance of mouse liver allograft[J].Am J Transplant.2010,10(1):40-46.
[51]Yang J,Riella LV,Boenisch O.etal.Paradoxical functions of B7:CD28 costimulation in a MHC class-Ⅱ-mismatched cardiac transplant model[J].Am J Transplant.2009,9(12):2837-2844.
[52]Asai T,Choi BK,Kwon PM,etal.Blockade of the 4-1BB(CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice[J].Immunology.2007,121(3):349-358.
[53]Ren XF,Luo KX,Zhang L.CD80 expression in biopsy from patients with chronic hepatitis B[J]. Med J Chin PLA.2000,25 (2):115.
[54]Gilani SR,Vuga LJ,LindellKO,etal.CD28 down-regulation on circulation CD4 T-cell is associated with poor prognoses of patients with idiopathic pulmonary fibrosis[J].PloS One.2010,5(1):e8959.
[55]佡剑非,冯涓.急性脑梗死患者CD4+CD28-T淋巴细胞和肿瘤坏死因子-α变化的研究[J].中国实用内科杂志.2007,27(12)：954-955.
[56]Hu W,Janke A,Ortler S,etal.Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies[J].Neurology.2007,68(4):277-282.